The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Al­most ex­act­ly three years af­ter Shang­hai-based Leg­end came out of nowhere to steal the show at AS­CO with jaw-drop­ping da­ta on their BC­MA-tar­get­ed CAR-T for mul­ti­ple myelo­ma, the lit­tle play­er with Big Phar­ma con­nec­tions is tak­ing a gi­ant step to­ward mak­ing it big on Wall Street. And this time they want to seal the deal on a glob­al rep af­ter stak­ing out a uni­corn val­u­a­tion in what’s turned out to be a bull mar­ket for biotech IPOs — in the mid­dle of a pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER